Pennant Group (PNTG) Chief Clinical Officer sells 1,394 shares in Rule 10b5-1 trade

Rhea-AI Filing Summary

Pennant Group, Inc. Chief Clinical Officer Jason Paul Steik reported a sale of 1,394 shares of common stock on 2026-08-06 at $38.522 per share in an open-market or private transaction. Following this transaction, he directly holds 15,106 shares of Pennant Group common stock. The trade was affirmed as made under a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 1,394 shares

Net Sell 1 txn

Insider Steik Jason Paul

Role Chief Clinical Officer

Sold 1,394 shs ($54K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,394	$38.522	$54K

Holdings After Transaction: Common Stock — 15,106 shares (Direct)

Key Figures

Shares sold: 1,394 shares Sale price: $38.522 per share Shares held after: 15,106 shares

3 metrics

Shares sold 1,394 shares Common stock sale on 2026-08-06 by Chief Clinical Officer

Sale price $38.522 per share Price for the 1,394-share sale on 2026-08-06

Shares held after 15,106 shares Direct common stock holdings following the reported sale

Key Terms

Rule 10b5-1, Form 4, open-market or private transaction

3 terms

Rule 10b5-1 regulatory

"affirmed under a Rule 10b5-1 trading plan checkbox"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Form 4 regulatory

"executive trading must be reported publicly on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market or private transaction financial

"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/10/2026 - 03:49 PM Accepted by SEC EDGAR 08/10/2026 - 03:48 PM Learn about SEC filing dates

FAQ

What insider transaction did Pennant Group (PNTG) report for Jason Paul Steik?

Pennant Group (PNTG) reported that Chief Clinical Officer Jason Paul Steik sold 1,394 shares of common stock on 2026-08-06. The sale was executed at a price of $38.522 per share in an open-market or private transaction.

How many Pennant Group (PNTG) shares does Jason Paul Steik hold after this Form 4 sale?

After the reported sale, Jason Paul Steik directly holds 15,106 shares of Pennant Group (PNTG) common stock. This figure reflects his position immediately following the 1,394-share disposition reported on 2026-08-06.

At what price did Jason Paul Steik sell Pennant Group (PNTG) shares?

Jason Paul Steik sold Pennant Group (PNTG) common stock at $38.522 per share. The transaction involved 1,394 shares and was coded as a sale in an open-market or private transaction on 2026-08-06.

Was the Pennant Group (PNTG) insider sale under a Rule 10b5-1 trading plan?

Yes. The filing indicates the transaction was affirmed under a Rule 10b5-1 trading plan. Such plans pre-arrange trading activity, which can reduce the informational value of the timing of this 1,394-share sale for investors.

What role does Jason Paul Steik hold at Pennant Group (PNTG)?

Jason Paul Steik is Pennant Group’s Chief Clinical Officer. In this capacity, he is an executive officer, and his sale of 1,394 shares at $38.522 per share must be reported publicly on Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Steik Jason Paul

(Last) (First) (Middle)

1675 E. RIVERSIDE DR

SUITE 150

(Street)

EAGLE IDAHO 83616

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pennant Group, Inc. [ PNTG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Clinical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		S		1,394	D	$38.522	15,106	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Kirk Cheney, as attorney in fact	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)